Assessing metastasis risk after pre‐operative anti‐angiogenic therapy
Abstract Anti‐angiogenic drugs are approved for the treatment of several cancer types, generally in the inoperable locally advanced or metastatic setting and in combination with other anti‐cancer agents. Recent clinical studies also suggest that anti‐angiogenic drugs can be useful in the pre‐operati...
Saved in:
| Main Authors: | Daniela Biziato, Michele De Palma |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2014-11-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.201404640 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy
by: Iris Uribesalgo, et al.
Published: (2019-06-01) -
PRL3-zumab as an anti-angiogenic therapy in neovascular eye diseases
by: Koon Hwee Ang, et al.
Published: (2025-05-01) -
Metabolic and hypoxic adaptation to anti‐angiogenic therapy: a target for induced essentiality
by: Alan McIntyre, et al.
Published: (2015-02-01) -
Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma.
by: Meser M Ali, et al.
Published: (2010-01-01) -
Anti-angiogenic effects of cationic zinc (II) phthalocyanine derivatives through photodynamic therapy
by: Seyma Isik, et al.
Published: (2025-01-01)